Format

Send to

Choose Destination
See comment in PubMed Commons below
Arch Otolaryngol Head Neck Surg. 2007 Jan;133(1):24-7.

Using comorbidity indexes to predict costs for head and neck cancer.

Author information

1
Department of Surgery, Penn State College of Medicine, Hershey, PA 17033, USA. chollenbeak@psu.edu

Abstract

OBJECTIVE:

To determine whether the general Charlson Comorbidity Index (CCI) and the head and neck cancer-specific Washington University Head and Neck Cancer Comorbidity Index (WUHNCCI) were useful for predicting cost of treatment for elderly patients with head and neck cancer.

DESIGN:

Retrospective, observational study.

PATIENTS:

A total of 1780 Medicare patients with head and neck cancer, who were treated between 1984 and 1994, were analyzed using the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database.

MAIN OUTCOME MEASURES:

Total Medicare payments were accumulated for each patient up to 1 and 5 years. Linear regression was used to estimate the impact of the comorbidity indexes on costs, controlling for demographics, site, stage, and treatment modality.

RESULTS:

Neither the WUHNCCI nor the CCI was significantly associated with 1-year costs. However, the effect of the WUHNCCI on 5-year costs was statistically significant (P<.001). A 1-point increase in the WUHNCCI from 4 to 5 was associated with an increase in 5-year costs of $2105. A 1-point increase in the WUHNCCI from 9 to 10 was associated with an increase in 5-year costs of $2837.

CONCLUSION:

These results suggest that comorbidity indexes for head and neck cancer may be useful for prognostication of patient outcomes and predicting costs.

PMID:
17224517
DOI:
10.1001/archotol.133.1.24
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center